Qualigen Therapeutics (FRA:7R90) EV-to-Revenue : (As of Jul. 02, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Qualigen Therapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Qualigen Therapeutics's enterprise value is €2.96 Mil. Qualigen Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00 Mil. Therefore, Qualigen Therapeutics's EV-to-Revenue for today is .

The historical rank and industry rank for Qualigen Therapeutics's EV-to-Revenue or its related term are showing as below:

During the past 5 years, the highest EV-to-Revenue of Qualigen Therapeutics was 30.05. The lowest was 0.19. And the median was 2.40.

FRA:7R90's EV-to-Revenue is not ranked ^*
in the Biotechnology industry.
Industry Median: 7.9
* Ranked among companies with meaningful EV-to-Revenue only.

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-07-02), Qualigen Therapeutics's stock price is €2.625. Qualigen Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was €0.00. Therefore, Qualigen Therapeutics's PS Ratio for today is .

Qualigen Therapeutics EV-to-Revenue Historical Data

The historical data trend for Qualigen Therapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Qualigen Therapeutics EV-to-Revenue Chart

Qualigen Therapeutics Annual Data

Trend

Mar20

Dec21

Dec22

Dec23

Dec24

EV-to-Revenue

3.91

Qualigen Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EV-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Qualigen Therapeutics's EV-to-Revenue

For the Biotechnology subindustry, Qualigen Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Qualigen Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Qualigen Therapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Qualigen Therapeutics's EV-to-Revenue falls into.

Save Embed

;

Save Embed

;

Qualigen Therapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Qualigen Therapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	2.962	/	0
	=

Qualigen Therapeutics's current Enterprise Value is €2.96 Mil.
Qualigen Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Qualigen Therapeutics (FRA:7R90) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Qualigen Therapeutics's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	2.625	/	0
	=

Qualigen Therapeutics's share price for today is €2.625.
Qualigen Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00.

Qualigen Therapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Qualigen Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Qualigen Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qualigen Therapeutics Inc (FRA:7R90) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

QLGN:USA

Address

5857 Owens Avenue, Suite 300, Carlsbad, CA, USA, 92008

Website

https://www.qlgntx.com

Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.

Qualigen Therapeutics Headlines

No Headlines